Citizens Maintains Market Outperform on Progyny, Raises Price Target to $31

Benzinga Newsdesk www.benzinga.com Positive 90.3%

Neg 0% Neu 0% Pos 90.3%

Citizens analyst Constantine Davides maintains Progyny (NASDAQ:PGNY) with a Market Outperform and raises the price target from $30 to $31.